Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters








Year range
2.
Hansen. int ; 35(1): 53-56, 2010.
Article in Portuguese | LILACS, SES-SP, SESSP-ILSLPROD, SES-SP, SESSP-ILSLACERVO, SES-SP | ID: lil-789330

ABSTRACT

Após re-introdução no mercado, a Talidomida tornou-se a droga mais eficaz no tratamento do eritema nodoso hânsenico, além de opção terapêutica para diversas doenças, como mieloma múltiplo. Contudo, o crescente uso desta, associado a corticóides sistêmicos e quimioterápicos, resultou em aumento de efeitos adversos pouco reconhecidos, como trombose venosa profunda.


After being reintroduced in the market, thalidomide has become the most effective drug in the treatment of erythema nodosum leprosum and a therapeutic option for several diseases, such as multiple myeloma. However, its increasing use, combined with systemic steroids and chemotherapy has also increased little recognized adverse effects, such as deep vein thrombosis.


Subject(s)
Humans , Male , Aged , Erythema Nodosum , Leprosy, Lepromatous , Leprosy/complications , Leprosy/drug therapy , Venous Thrombosis/etiology , Femoral Vein , Adrenal Cortex Hormones/adverse effects , Thalidomide/adverse effects , Venous Thrombosis/diagnosis
SELECTION OF CITATIONS
SEARCH DETAIL